Clinical Trials Browser

INDUSTRY × relatlimab × Clear all

NCT06743126 2026-04-13

SUPRAME

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

NCT01968109 2026-04-06

An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors

Phase 1/2 Completed

1,482 enrolled 56 charts

Neoplasms by Site

NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

229 enrolled 21 charts

Advanced Cancer

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

Neoplasms

NCT06561386 2026-03-31

RELATIVITY1093

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05176483 2026-03-12

STELLAR-002

Phase 1 Recruiting

GastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT07459543 2026-03-09

A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India

Phase 4 Not yet recruiting

Melanoma, Skin Neoplasms

NCT05255601 2026-02-25

RELATIVITY-069

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT06880549 2026-02-05

A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors

Phase 1 Active not recruiting

Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence

NCT05337137 2026-01-12

RELATIVITY-106

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT04567615 2026-01-08

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Phase 2 Completed

266 enrolled 28 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05002569 2026-01-08

RELATIVITY-098

Phase 3 Terminated

1,093 enrolled 15 charts

Melanoma

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Melanoma

NCT02060188 2025-11-06

CheckMate142

Phase 2 Completed

385 enrolled 17 charts 4 FDA

GastrointestinalOther solid neoplasm

Microsatellite Unstable Colorectal Cancer

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Phase 1 Terminated

Uveal Melanoma

NCT04623775 2025-10-20

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

Phase 2 Active not recruiting

468 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

Melanoma

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 2 FDA

Melanoma, Neoplasms

NCT05625399 2025-08-24

RELATIVITY-127

Phase 3 Active not recruiting

Melanoma

NCT02966548 2025-02-17

Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors

Phase 1 Completed

Neoplasms

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

Phase 1 Terminated

Melanoma

NCT03310619 2024-04-04

PLATFORM

Phase 1/2 Completed

62 enrolled 41 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT05498480 2024-02-20

RELATIVITY-111

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02488759 2023-11-13

CheckMate358

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

NCT02935634 2023-06-09

FRACTION-GC

Phase 2 Completed

190 enrolled 25 charts

Gastrointestinal

Advanced Gastric Cancer

NCT04112498 2023-04-06

A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab

Phase 1 Completed

Neoplasms

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Completed

106 enrolled 27 charts

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT02996110 2022-12-19

FRACTION-RCC

Phase 2 Completed

182 enrolled 23 charts

Advanced Cancer

NCT03335540 2022-09-26

ADVISE

Phase 1 Completed

Advanced Cancer

NCT02750514 2021-03-22

FRACTION-Lung

Phase 2 Terminated

295 enrolled 21 charts

Advanced Cancer

NCT03704077 2020-05-19

An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Stomach Neoplasms